SGX393 inhibits the CML mutant Bcr-AblT315I and preempts in vitro resistance when combined with nilotinib or dasatinib. (Q36535476)
Jump to navigation
Jump to search
scholarly article
Language | Label | Description | Also known as |
---|---|---|---|
English | SGX393 inhibits the CML mutant Bcr-AblT315I and preempts in vitro resistance when combined with nilotinib or dasatinib. |
scholarly article |
Statements
SGX393 inhibits the CML mutant Bcr-AblT315I and preempts in vitro resistance when combined with nilotinib or dasatinib (English)
Thomas O'Hare
Christopher A Eide
Amie S Corbin
Matthew J Wong
Sean Buchanan
Kevin Holme
Katayoun A Jessen
Crystal Tang
Hal A Lewis
Richard D Romero
Michael W Deininger
26 March 2008
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference